Table 2.
Kidney replacement therapy
| Reasons for CKRT | |
| AKI stage 2 (KDIGO) | 6 (30) |
| AKI stage 3 (KDIGO) | 11 (55) |
| Hyperkalemia | 2 (10) |
| Lactate acidosis | 1 (5) |
| Dialyzer | Fresenius MultiFiltrate circuit (MultiFiltrate Ultraflux® AV 1000S) |
| CVVHD (CiCa®)/CVVHDF (MultiBic®, post-dilution) | 15 (75)/5 (25) |
| Clotting | 2 (13.3)/2 (40) |
| Blood flow (ml/min) | 100 [100, 162] |
| CVVHD | 100 [100, 100] |
| CVVHDF | 200 [200, 300] |
| Dialysate flow (ml/h) | 2000 [2000, 2125] |
| Substitute flow (if CVVHDF) (ml/h) | 2000 [1000, 3500] |
| Anticoagulation | |
| Citrate | 15 (75) |
| Unfractioned Heparin < 1000 IE/h | 8 (40) |
| Unfractioned Heparin > 1000 IE/h | 4 (20) |
| Agatrobane | 5 (25) |
| None | 3 (15) |
CKRT continuous kidney replacement therapy, CVVHD(F) continuous veno-venous hemodialysis/hemodiafiltration